hVIVO PLC
LSE:HVO
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
UK |
hVIVO PLC
LSE:HVO
|
184m GBP | 5.4 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.8B USD | 4.9 | ||
US |
Danaher Corp
NYSE:DHR
|
194.8B USD | 3.6 | ||
CH |
Lonza Group AG
SIX:LONN
|
36.1B CHF | 3.8 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
39.9B USD | 6.3 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
53.4T KRW | 5.3 | ||
US |
Agilent Technologies Inc
NYSE:A
|
38.8B USD | 6.2 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
30.7B USD | -193.6 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26.4B USD | 2.8 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
23B USD | 8.6 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
17B EUR | 4.4 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.